Los Angeles, CANCT07287098Now EnrollingIRB Ready

Breast Neoplasms Clinical Trial in Los Angeles, CA

Access cutting-edge breast neoplasms treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Eli Lilly and Company

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access breast neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related breast neoplasms treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this breast neoplasms clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Breast Neoplasms Study in Los Angeles

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days. Cohort 2: will help researchers understand how imlunestrant affects the ovaries when it is taken without ovarian suppression. Researchers will compare the effects to those of another medicine called tamoxifen. This group will also include premenopausal women with the same type of breast cancer. The treatment in this group will last for up to 6 months.

Sponsor: Eli Lilly and Company

Who Can Participate

Inclusion Criteria

Have histologically confirmed Stage I to III Estrogen Receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) invasive breast carcinoma with Ki-67 at least 10%
Be willing and able to provide pre- and on-treatment tumor samples.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Be able to swallow capsules or tablets.
Be premenopausal women.
If of childbearing potential must use 1 highly effective method of non-hormonal contraception while receiving study treatment and for the duration specified in protocol.
Have adequate organ function. Cohort 2:
Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis
Have undergone definitive loco-regional therapy.
Have received at least 4.5 years of any adjuvant endocrine therapy (ET), or at least 2 years of adjuvant ET with no additional ovarian suppression planned.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Be able to swallow capsules or tablets.
Be premenopausal women
If of childbearing potential must use 1 highly effective method of non-hormonal contraception while receiving study treatment and for the duration specified in protocol.
Have adequate organ function.

Exclusion Criteria

Have bilateral invasive metastatic, occult primary, or inflammatory breast cancer.
Have had prior bilateral oophorectomy or ovarian ablation.
Have a serious medical condition
Had major surgery within 28 days prior to randomization.
Have a history of other cancer (except non melanoma skin cancer, Stage I uterine cancer, or carcinoma in situ of the cervix or other in situ cancer), unless in complete remission with no therapy for a minimum of 1 year.
Plan to receive concurrent neoadjuvant therapy with any other non-protocol anticancer therapy.
Have had any prior therapy for an invasive or non-invasive breast cancer.
Have had prior radiotherapy to the ipsilateral chest wall for any malignancy.
Have received prior anti-estrogen therapy, including for osteoporosis or prevention of breast cancer.
Have had prior treatment with any Gonadotropin-releasing hormone (GnRH) agonist within 12 months prior to randomization.
Receiving current exogenous reproductive hormone therapy Cohort 2:
Have ovarian cyst(s) greater than (\>) 1 centimeter (cm) at screening.
Have metastatic occult primary, or inflammatory breast cancer.
Have had prior bilateral oophorectomy or ovarian ablation.
Have a serious medical condition
Had major surgery within 28 days prior to randomization.
Have a history of other cancer (except non melanoma skin cancer or carcinoma in situ of the cervix or other in situ cancer), unless in complete remission with no therapy for a minimum of 1 year.
Completed or discontinued prior adjuvant ET \>6 months prior to screening.
Have received prior therapy with any selective estrogen receptor degrader (SERD).
Receiving current exogenous reproductive hormone therapy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT07287098) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Neoplasms Treatment Options in Los Angeles, CA

If you're searching for breast neoplasms treatment options in Los Angeles, CA, this clinical trial (NCT07287098) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced breast neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast neoplasms clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Los Angeles, CA

See all breast cancer clinical trials recruiting in Los Angeles — not just this study.

Browse Breast Cancer Trials in Los Angeles →

Browse More Trials by Condition

Breast Cancer TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA